Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
The deal is a late entrant into 2020's top five mergers and acquisitions.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Welcome to the calm before the Covid-19 storm.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Suddenly 2020’s medtech M&A landscape looks very different.